Evidence map›Paper›PMID 36443337›Full record

ArticleNature communications2022

Extensive germline-somatic interplay contributes to prostate cancer progression through HNF1B co-option of TMPRSS2-ERG.

Nikolaos Giannareas, Qin Zhang, Xiayun Yang, Rong Na, Yijun Tian, Yuehong Yang, Xiaohao Ruan, Da Huang, Xiaoqun Yang, Chaofu Wang and 4 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 4 countries.

Nikolaos Giannareas *Disease Networks Research Unit, Faculty of Biochemistry and Molecular Medicine & Biocenter Oulu, University of Oulu, Oulu, Finland.
Qin Zhang *Disease Networks Research Unit, Faculty of Biochemistry and Molecular Medicine & Biocenter Oulu, University of Oulu, Oulu, Finland.
Xiayun Yang *Disease Networks Research Unit, Faculty of Biochemistry and Molecular Medicine & Biocenter Oulu, University of Oulu, Oulu, Finland.
Rong Na *Division of Urology, Department of Surgery, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong, China.ORCID 0000-0001-7470-5108
Yijun TianDepartment of Tumour Biology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Yuehong YangDisease Networks Research Unit, Faculty of Biochemistry and Molecular Medicine & Biocenter Oulu, University of Oulu, Oulu, Finland.
Xiaohao RuanDepartment of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Da HuangDepartment of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Xiaoqun YangDepartment of Pathology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Chaofu WangDepartment of Pathology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Peng ZhangFudan University Shanghai Cancer Center & MOE Key Laboratory of Metabolism and Molecular Medicine and Department of Biochemistry and Molecular Biology of School of Basic Medical Sciences, Shanghai Medical College of Fudan University, Shanghai, China.
Aki ManninenDisease Networks Research Unit, Faculty of Biochemistry and Molecular Medicine & Biocenter Oulu, University of Oulu, Oulu, Finland.ORCID 0000-0002-6263-8101
Liang WangDepartment of Tumour Biology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.ORCID 0000-0002-9364-8572
Gong-Hong WeiDisease Networks Research Unit, Faculty of Biochemistry and Molecular Medicine & Biocenter Oulu, University of Oulu, Oulu, Finland. gonghong_wei@fudan.edu.cn.ORCID 0000-0001-6546-9334
Ruijin Hospital · CNUniversity of Oulu · FIMoffitt Cancer Center · USShanghai Medical College of Fudan University · CNChinese University of Hong Kong · HK

Funding

Genetic determinants of gene expression phenotypes in aggressive prostate cancerR01CA157881 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI WANG, LIANG · 2011 to 2016
$2.9M
Functional characterization of prostate cancer risk loci by high throughput sequencingR01CA250018 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI WANG, LIANG · 2020 to 2023
$1.5M
NCI NIH HHS R01 CA157881NCI NIH HHS R01 CA250018
6 · The paper itself

Abstract

Genome-wide association studies have identified 270 loci conferring risk for prostate cancer (PCa), yet the underlying biology and clinical impact remain to be investigated. Here we observe an enrichment of transcription factor genes including HNF1B within PCa risk-associated regions. While focused on the 17q12/HNF1B locus, we find a strong eQTL for HNF1B and multiple potential causal variants involved in the regulation of HNF1B expression in PCa. An unbiased genome-wide co-expression analysis reveals PCa-specific somatic TMPRSS2-ERG fusion as a transcriptional mediator of this locus and the HNF1B eQTL signal is ERG fusion status dependent. We investigate the role of HNF1B and find its involvement in several pathways related to cell cycle progression and PCa severity. Furthermore, HNF1B interacts with TMPRSS2-ERG to co-occupy large proportion of genomic regions with a remarkable enrichment of additional PCa risk alleles. We finally show that HNF1B co-opts ERG fusion to mediate mechanistic and biological effects of the PCa risk-associated locus 17p13.3/VPS53/FAM57A/GEMIN4. Taken together, we report an extensive germline-somatic interaction between TMPRSS2-ERG fusion and genetic variations underpinning PCa risk association and progression.

Indexed as

Genome-Wide Association StudyProstatic NeoplasmsGerm CellsHepatocyte Nuclear Factor 1-betaHumansMaleOncogene Proteins, FusionPelvisProstateSerine EndopeptidasesTranscriptional Regulator ERGERG protein, humanHepatocyte Nuclear Factor 1-betaHNF1B protein, humanOncogene Proteins, FusionSerine EndopeptidasesTMPRSS2-ERG fusion protein, humanTMPRSS2 protein, humanTranscriptional Regulator ERG

Identifiers

PMID36443337
PMCPMC9705428
OpenAlexW4310193548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.